en

School of Pharmacy Projects MRC IMPACT Doctoral Training Partnership

School of Pharmacy Projects MRC IMPACT Doctoral Training Partnership

United Kingdom 02 Mar 2021
University of Nottingham

University of Nottingham

State University, Browse similar opportunities

OPPORTUNITY DETAILS

Total reward
0 $
State University
Area
Host Country
Deadline
02 Mar 2021
Study level
Opportunity type
PhD
Specialities
Opportunity funding
Not funding
Eligible Countries
This opportunity is destined for all countries
Eligible Region
All Regions

Reference SCI1971

Closing Date Tuesday, 2nd March 2021

Department Pharmacy

Applications are open for a range of exciting projects around the theme of complex disease.

These 42-month PhD studentships, starting in October 2021, are offered through IMPACT – a doctoral training partnership between the Universities of Birmingham, Leicester and Nottingham. The University of Nottingham is advertising 8 projects in order to recruit to 4 studentships (2 IMPACT and 2 iCASE) in total.

You will study alongside other PhD students across a diverse range of projects, enabling you to think creatively and perform innovative, world- leading research. You will also benefit from the expertise of our research partner, the Research Complex at Harwell.

Applications will close at 5.00 pm on 7 January 2021. Funding is provided by the Medical Research Council. Please ensure that your application is submitted with all required documentation as incomplete applications will not be considered.

Full information about the eligibility criteria and application process are on the MRC IMPACT DTP website.

The following iCASE projects are available in the School of Pharmacy:

Development of an intradermal or inhaled DNA vaccine for COVID-19 and beyond - James Dixon with Scancell (SME) 

Intradermal and inhaled delivery of nucleic acid vaccines could be clinically effective, safe and globally-deployable against multiple complex diseases. This project will aim to combine physical and peptide-based delivery systems to enhance the efficacy and application of such technologies to the COVID-19 vaccine (‘Covidity’) presently under-development by our consortium (funded by Innovate-UK). This PhD will formulate and test combined systems for skin and lung-focused vaccine delivery in ex vivo tissue models, then move to rodent models, examining virus neutralisation, T cell responses and protection in virally challenged animals. The platform technology optimised and demonstrated will have wide ranging impact on future applications of nucleic acid vaccine approaches (including DNA, mRNA and oligo-based methods). The PhD will also directly aid attempts to translate antibody and peptide-engineering knowhow to generate a rapidly deployable and safe immunisation system for multiple complex diseases.

Translation of novel polymer anti-bacterial coating to invasive medical devices used in the neonatal intensive care for high risk preterm infants - Morgan Alexander with Camstent Ltd (SME) & the Research Complex at Harwell

Infections in premature babies are a leading cause of death, severe illness and are associated with poor long-term outcomes for survivors. Premature babies on intensive care units acquire these infections whilst in hospital, often from their life-supporting medical devices. This studentship will develop new coatings for these devices that resist bacterial colonisation and so reduce the risk of infection in these vulnerable babies. Based in the world-leading School of Pharmacy at the University of Nottingham, in partnership with academic neonatologists in the School of Medicine, the student will develop the new coatings, test them in vitro and in vivo, working closely with our industrial collaborator. There will be opportunities to train at the Harwell Research Complex learning cutting edge skills and spend time in the hospital environment, in a large research-active neonatal intensive care unit, to better understand the clinical need. This PhD will suit a highly ambitious science graduate, in the field of biology or chemistry, who wishes to undertake a truly translational clinical project with industry collaboration and training. It is expected that at the end of the project, the student will be well placed to secure follow-on funding for clinical trials and on-going development or commercialisation.

Other organizations


Choose your study destination


Choose the country you wish to travel to study for free, work or volunteer

Please find also